Neuroene Therapeutics develops proprietary VK analogs that target mitochondrial dysfunction, a common factor in neurological diseases such as medication-resistant epilepsy, Parkinson's, and rare mitochondrial disorders. Their orally bioavailable compounds demonstrate excellent brain penetration and half-life, addressing the critical need for effective treatments in this area.
Funding
$400K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many neurological diseases, including medication-resistant epilepsy, Parkinson's, and rare mitochondrial disorders, share a common characteristic: mitochondrial dysfunction. There is a significant unmet need for treatments that address this underlying issue across a wide range of neurological conditions.
Solution
Neuroene Therapeutics develops a novel class of proprietary Vitamin K (VK) analogs designed to target mitochondrial health and energetics. These orally bioavailable compounds are engineered for excellent brain penetration and half-life, offering a potential therapeutic approach for neurological diseases linked to mitochondrial dysfunction. By addressing the root cause of these conditions, Neuroene aims to provide effective treatments where limited options currently exist.
Target Audience
The primary target audience includes patients suffering from medication-resistant epilepsy, Parkinson's disease, and rare mitochondrial disorders, as well as the physicians and specialists who treat these conditions.
Features
- Proprietary VK analogs with a central naphthoquinone moiety that targets mitochondrial health.
- Orally bioavailable compounds for convenient administration.
- Demonstrated excellent brain penetration, enabling targeted drug delivery to the central nervous system.
- Optimized half-life for sustained therapeutic effect.
- Patented treatment for multiple disease indications, including epilepsy, Parkinson's, and rare mitochondrial disorders.